Teva Pharmaceutical Industries (TEVA) reported Q4 non-GAAP earnings Wednesday of $0.71 per diluted share, down from $1.00 a year earlier.
Analysts polled by FactSet expected $0.71.
Net revenue for the quarter ended Dec. 31 was $4.23 billion, down from $4.46 billion a year earlier.
Analysts surveyed by FactSet expected $4.15 billion.
For 2025, the drug maker said it expects non-GAAP diluted EPS of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect non-GAAP EPS of $2.96 on revenue of $17.09 billion.
Teva shares were down by more than 5% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.